Very promising but still in vivo: Researchers develop technology to change protein identity in vivo

[Maxone73]

Aka how to mitigate side effects of most radio ligands and drugs!

news-medical.net/news/20241...

[NPfisherman]

Maximus,

Thanks for posting...more precision medicine.. like a smart bomb...drops off the payload to kill the enemy...

The war on cancer continues, but I feel like we are getting closer to the victory of chronic disease status...I believe that we will see another jump in 5 year survival rate... maybe to 45%... Now, if we could get every MD to best practice SOC, then look to higher rate....still some show up on lupron only...

DD

[Maxone73 in reply to NPfisherman]

You are right Don! When triplet therapy will become a standard, I am quite sure that we will reach 50% OS for metastatic disease in 5 years...I don't want to be too positive but by the numbers it could even be progression free at 50% in 5 years, which would be even better

[NPfisherman in reply to Maxone73]

Maximus,

I will not debate the value of the addition of docetaxel in higher volume disease for SOC, but in low volume disease (MHSPC), there is no proof that I am aware of that triplet therapy provides an improvement in OS for low volume disease vs ARSI plus ADT.:

pubmed.ncbi.nlm.nih.gov/385...

I know that some posters(or at least one) on another forum say that triplet therapy for all rule should be applied. As a provider, I can tell you that docetaxel has quite a few interactions with other drugs plus SEs...

mayoclinic.org/drugs-supple...

Peripheral neuropathy is no pleasure cruise post chemo, and for those suffering in early stages of it before chemo, docetaxel can worsen it significantly. As a provider, I have also always believed in first do no harm, but as we know, not all posters are held to that same standard. I'm not here by accident. Standing up for SBRT in oligometastatic prostate cancer helped get me here... Free speech is sometimes a one way street depending on who is in charge...

The Iron Don

[Maxone73 in reply to NPfisherman]

Aranote trial would say you are right as well